Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Transgene

Transgene
1979 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
TNG STOCK SYMBOL
1 INVESTMENTS
$2.85 SHARE PRICE (As of Tuesday Closing)
Description

Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States. Its subsidiary represents the company before various bodies, regulatory authorities and clinical sites for clinical trials it conducts in the US.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 400 Boulevard Gonthier d'Andernach
  • Parc d'Innovation
  • 67405 Illkirch-Graffenstaden
  • France

+33 03 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Transgene’s full profile, request a free trial.

Transgene Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.72 - $3.78 $182M $2.80 $0.15 52.3K 63.9M

Transgene Financials Summary

In Thousands,
USD
TTM
31-Dec-2018
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 223,395 218,145 215,590 131,945
Revenue 1,575 1,575 2,367 2,595
EBITDA 11,516 11,516 (34,490) (24,242)
Net Income 9,471 9,471 (36,397) (27,883)
Total Assets 124,163 124,163 121,018 129,307
Total Debt 42,736 42,736 45,511 64,985
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Transgene Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Transgene‘s full profile, request access.

Request full access to PitchBook

Transgene Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genfit Formerly VC-backed Loos, France 000 00000 000000000. 0 00000
00000 000000000000 Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
0000000 Formerly VC-backed Marseille, France 00 000.00 000000&0 000.00
000000 00000000000 Venture Capital-Backed San Diego, CA 000.00 00000000000 000.00
00000000 Corporate Backed or Acquired Planegg, Germany 000 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Transgene Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000 (0 01-Jan-2010 00000 0000000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Transgene Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 00000 (0 01-Jan-2010 00000 0000000 Completed
  • 2 buyers
To view this company’s complete exits history, request access »

Transgene Executive Team (4)

Name Title Board
Seat
Contact
Info
Philippe Archinard Ph.D Chief Executive Officer & Chairman
Eric Quéméneur Ph.D Executive Vice President & Vice President, Research & Development
Thibaut Du Fayet Vice President, Alliance Management, Project Management & Marketing
Maud Brandely Ph.D Chief Medical Officer

Transgene Board Members (10)

Name Representing Role Since Contact
Info
00000 0é00000 Self Board Member 000 0000
0000000 0é000 Transgene Independent Director & Chairman of the Compensation Committee 000 0000
000000 000000 Self Independent Director & Chairman, Compensation Committee 000 0000
0000-0000ç000 0000é Self Board Member 000 0000
0000-000 0é0000000 Transgene Director 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »